Adolescents and caregivers navigate complex decision-making, appetite changes, and stigma when using weight loss medications.

Obesity in adolescents and young adults (AYAs) is a growing public health concern, often requiring multifaceted interventions. While weight loss medications like semaglutide, liraglutide, and tirzepatide have demonstrated clinical efficacy in adults, understanding the real-world experiences, decision-making processes, and psychosocial impacts in the younger population is crucial. Current care often lacks a comprehensive framework for shared decision-making, particularly concerning the unique challenges AYAs face with body image, peer influence, and long-term medication adherence. This study addresses this gap by exploring the lived experiences of AYAs and their caregivers.

Researchers conducted a qualitative study involving 29 adolescents and young adults (AYAs) aged 12-22 years with obesity, alongside 23 caregivers. Participants were either considering starting (PRE, n=9 AYA, n=7 caregivers) or already using (POST, n=20 AYA, n=16 caregivers) weight loss medications, including semaglutide, liraglutide, tirzepatide, or phentermine ± topiramate. Semistructured interviews were audio-recorded via video conferencing. A rapid qualitative analysis approach was employed to identify and summarize key themes regarding decision-making, eating behaviors, and overall experiences.